Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P. J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S. D., Barlési, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verriele, V., Haddad, V., Ferretti, G., Cortot, A., De Fraipont, F., Jimenez, M., Hoog-Labouret, N., & Vassal, G. (2019). crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Annals of oncology, 30, 1985–1991. http://access.bl.uk/ark:/81055/vdc_100098454627.0x000029